This Specialized Resource will provide chemical expertise and produce imaging agents that are not commercially available. These agents will be a) rigorously tested so as to conform to strict standards (by being synthesized under standardized conditions in technically adequate ways);b) analyzed according to a standard protocol prior to use;and c) synthesized in sufficient amounts for in vivo use. They will be available to all Project researchers. As it has in the past, this Resource will also conduct its own research in order to further improve synthetic conditions, and to design fluorochromes, sensors, tags, linkers and nanoparticulate carriers.
The specific aims of this Specialized Resource are to synthesize and provide: 1) an array of new fluorochromes, fluorescently labeled reagents, sensors, and coupling reagents;2) nanomaterial based imaging agents;and 3) radiochemistry expertise and novel ''^F-imaging agents. The existence of this Specialized Resource has a number of benefits to the overall Program, these include: a) access to cutting edge synthetic, bioconjugate and analytical chemistry;b) access to radiochemistry;c) access to well validated imaging compounds that are not commercially available;d) capabilities for scaling up the synthesis of novel compounds;and e) access to specific training. By centralizing personnel, resources and supplies, the Chemistry Resource is able to provide these functions extremely efficiently and at a reduced overall cost.

Public Health Relevance

This Chemistry Resource is an integral part of this P50 Program, providing essential compounds that are not commercially available to all Projects and Developmental Projects. This Resource also scales up imaging agents for in vivo use and carries out rigorous quality assurance.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA086355-14
Application #
8566736
Study Section
Special Emphasis Panel (ZCA1-SRLB-9)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
14
Fiscal Year
2013
Total Cost
$81,385
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Keliher, Edmund J; Klubnick, Jenna A; Reiner, Thomas et al. (2014) Efficient acid-catalyzed (18) F/(19) F fluoride exchange of BODIPY dyes. ChemMedChem 9:1368-73
Dubach, J Matthew; Vinegoni, Claudio; Weissleder, Ralph (2014) Steady state anisotropy two-photon microscopy resolves multiple, spectrally similar fluorophores, enabling in vivo multilabel imaging. Opt Lett 39:4482-5
Pittet, Mikael J; Nahrendorf, Matthias; Swirski, Filip K (2014) The journey from stem cell to macrophage. Ann N Y Acad Sci 1319:1-18
Thurber, Greg M; Reiner, Thomas; Yang, Katherine S et al. (2014) Effect of small-molecule modification on single-cell pharmacokinetics of PARP inhibitors. Mol Cancer Ther 13:986-95
Courtis, Alexandra M; Santos, Sofia A; Guan, Yinghua et al. (2014) Monoalkoxy BODIPYs--a fluorophore class for bioimaging. Bioconjug Chem 25:1043-51
Hideshima, T; Mazitschek, R; Santo, L et al. (2014) Induction of differential apoptotic pathways in multiple myeloma cells by class-selective histone deacetylase inhibitors. Leukemia 28:457-60
Kim, Eunha; Yang, Katherine S; Giedt, Randy J et al. (2014) Red Si-rhodamine drug conjugates enable imaging in GFP cells. Chem Commun (Camb) 50:4504-7
Dubach, J M; Vinegoni, C; Mazitschek, R et al. (2014) In vivo imaging of specific drug-target binding at subcellular resolution. Nat Commun 5:3946
Turetsky, Anna; Kim, Eunha; Kohler, Rainer H et al. (2014) Single cell imaging of Bruton's tyrosine kinase using an irreversible inhibitor. Sci Rep 4:4782
Aceto, Nicola; Bardia, Aditya; Miyamoto, David T et al. (2014) Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell 158:1110-22

Showing the most recent 10 out of 266 publications